Theragen Unveils New Insights into Patient Recovery with ActaStim®-S at SMISS 2026 Forum

In a remarkable presentation at the Society for Minimally Invasive Spine Surgery (SMISS) 2026 Annual Forum, Theragen, a notable medical device company from Jacksonville, Florida, introduced new findings that illuminate how certain patient demographics, health conditions, and surgical methods can predict recovery outcomes following spinal fusion surgery using their innovative ActaStim®-S bone growth stimulator.

Chris McAuliffe, CEO of Theragen and a co-inventor of the ActaStim®-S, emphasized the device's dual role in both delivering therapy and collecting valuable data. Over nearly 7,000 patients and 200,000 days of recovery data, the device has revealed consistent patterns in recovery, challenging the notion that recovery is random. This innovation aims to more accurately identify patients in need of additional support throughout their recovery journey.

The ActaStim®-S integrates a clinically validated electrical signal with an easy-to-wear design, making it suitable for continuous use. This unique combination enhances the likelihood of successful spinal fusion outcomes while remaining discreet and comfortable for real-life patient use.

Key Findings Presented

Theragen shared insightful findings derived from their recent research and analysis, including:
1. Clinical Predictors of Pain Improvement: The data highlighted that wear adherence to the bone growth stimulator is the strongest modifiable predictor for clinically significant pain improvement post-surgery. Remarkably, improvement correlated positively with daily usage, peaking at approximately 13 hours of wear before leveling off.
2. Machine Learning Insights: Utilizing machine learning, Theragen demonstrated that their advanced models, including XGBoost, outperformed traditional methods when predicting clinically meaningful pain improvement in patients. This approach not only supports the understanding of patient recovery but also serves in developing efficient risk-stratification tools for postoperative care.
3. Longitudinal Dataset Impact: A novel approach to analyzing the available data led to a more granular view of patient and surgical factors related to postoperative pain. Factors like degenerative disc disease and certain surgical approaches showed significant statistical connections to varying pain trajectories, allowing for tailored support throughout recovery.

Ryan D. Snowden, MD, an orthopedic surgeon specializing in spine surgery, supported the findings, indicating the promising implications for individualizing patient care based on observed patterns. Early identification of patients less likely to achieve significant pain relief could be pivotal in shaping recovery plans and improving overall patient satisfaction.

Looking Ahead

Chris Mills, Chief Marketing Officer at Theragen, underscored the commitment of the company towards translating complex data into actionable insights for patients and healthcare providers alike. The findings from ActaStim®-S are more than mere numbers; they can serve as guidance for navigating the intricate landscape of spinal surgery recovery.

As Theragen continues to innovate and expand its reach, the ActaStim®-S stands as a testament to the potential of non-invasive medical technology in optimizing patient outcomes. It opens new avenues for research, engagement, and, ultimately, patient empowerment in their recovery processes.

For more about Theragen and their advancements in spinal health technology, visit actastim.com.

About Theragen

Theragen, Inc. is a leader in developing and manufacturing non-invasive electrical stimulation devices aimed at improving surgical outcomes and enhancing patient engagement in recovery. Their commitment to innovation remains pivotal in the healthcare landscape, continuing to help patients regain their quality of life.